// App-Quantinova.ai

e23244 : Evaluation of the prognostic value of RANK, RANKL, OPG and OPN mRNA expression in high-risk early breast cancer patients treated with anthracycline-containing adjuvant chemotherapy.

Researchers

Presenter

  • Eleni Timotheadou

Principal Investigators

  • Flora Zagouri

  • Zoi Alexopoulou

  • Ralph M Wirtz

  • Helen Gogas

  • Vasilios Karavasilis

  • Elke Veltrup

  • George Klouvas

  • George E. Pentheroudakis

  • Angelos Koutras

  • Maria Sotiropoulou

  • Alexandra Papoudou-Bai

  • Helena Linardou

  • Pavlos Papakostas

  • Gerasimos Aravantinos

  • Paris A. Kosmidis

  • Maria Skondra

  • Meletios A. Dimopoulos

  • George Fountzilas

Medical Centers

  • Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece

  • Health Data Specialists Ltd, Athens, Greece

  • STRATIFYER Molecular Pathology GmbH, Cologne, Germany

  • On behalf of the Hellenic Group of Young Oncologists (HeGYO), under the auspices of the Hellenic Society of Medical Oncology (HeSMO), Athens, Greece

Locations

  • Germany

  • Greece

Companies

  • Health Data Speciali

  • STRATIFYER Molecular

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • Osteopontin

  • Osteoprotegerin

  • Receptor activator of nuclear factor kappa-Β ligand

  • Receptor activator of nuclear factor κ B

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Epirubicin

  • Paclitaxel

  • Filgrastim

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved